SEC Comment Letter 0000000000-23-010300 to ENvue Medical, Inc. (FEED)
ENvue Medical, Inc.
Date: Sept. 19, 2023 · CIK: 0001326706 · Accession: 0000000000-23-010300
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274482
Letter
United States securities and exchange commission logo September 19, 2023 Brian Murphy Chief Executive Officer NanoVibronix, Inc. 525 Executive Blvd Elmsford, New York 10523 Re:NanoVibronix, Inc. Registration Statement on Form S-3 Filed September 12, 2023 File No. 333-274482 Dear Brian Murphy: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Nicholas O'Leary at 202-551-4451 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Jayun Koo, Esq.
Show Raw Text
United States securities and exchange commission logo
September 19, 2023
Brian Murphy
Chief Executive Officer
NanoVibronix, Inc.
525 Executive Blvd
Elmsford, New York 10523
Re:NanoVibronix, Inc.
Registration Statement on Form S-3
Filed September 12, 2023
File No. 333-274482
Dear Brian Murphy:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Nicholas O'Leary at 202-551-4451 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Jayun Koo, Esq.